Yahoo Web Search

  1. Ads
    related to MERCK & CO., INC
  1. NYSE: WST) Aclaris Therapeutics Inc (NASDAQ: ACRS) Acorda Therapeutics Inc (NASDAQ: ACOR) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Fulcrum Therapeutics Inc (NASDAQ ...

  2. AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study

    Zacks via Yahoo FinanceAug 21 14:50 PM

    AstraZeneca plc’s AZN late-stage study evaluating its PD-L1 inhibitor Imfinzi for the first line treatment of certain lung cancer patients failed to meet the primary endpoint. The phase III ...

  3. Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 01 16:23 PM

    John Leonard -- President and Chief Executive Officer Yeah. We don't give many details, but for the purposes of the tox work and getting in the clinical, it's a collection of different suppliers ...

  4. Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 10 5:43 AM

    Thank you for standing by and welcome to the Agenus Second Quarter 2019 Conference Call. In the first half of 2019, we have continued to deliver new discoveries to the clinic, and advance our ...

  5. Moleculin Completes Enrollment in Early-Stage Cancer Study

    Zacks via Yahoo FinanceAug 15 11:55 AM

    Moleculin Biotech, Inc. MBRX announced that it has completed enrollment in the proof-of-concept clinical study evaluating its p-STAT3 inhibitor candidate, WP1220...skin cancer. The company ...

  6. Who is next in big pharma's merger spree?

    Reuters via Yahoo FinanceAug 19 19:20 PM

    Bristol-Myers Squibb's $74 billion acquisition of Celgene set the M&A ball rolling in January, and was followed by AbbVie Inc's $63 billion bid for troubled smaller rival Allergan Plc ...

  7. PD-L1 inhibitors available on the market are Merck’s MRK Keytruda, AstraZeneca’s AZN Imfinzi, Bristol Myers’ BMY Opdivo, Roche’s Tecentriq and Pfizer’s PFE Bavencio. ...

  8. Here's Why Procter & Gamble is a Hot Investment Pick Now

    Zacks via Yahoo FinanceAug 12 13:03 PM

    The Procter & Gamble Company PG, popularly known as P&G, appears to be a solid bet driven by continued investments to aid business growth. Moreover, it remains focused on product improvement ...

  9. In a separate press release, AstraZeneca announced that the phase III study (PAOLA-1) evaluating its and Merck's MRK PARP inhibitor, Lynparza, for a broader advanced ovarian cancer patient ...

  10. Edited Transcript of REGN earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceAug 14 16:35 PM

    Leonard S., Regeneron Pharmaceuticals, Inc. - Co-Founder, President, CEO & Executive Director [3...like to extend a warm welcome to Justin, who joined us early this summer after ...

  1. Ads
    related to MERCK & CO., INC